ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer A Nonrandomized Clinic
Han, H.S. et al; JAMA Oncology 2025
Read More
-
Adjuvant endocrine therapy with cyclindependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/ HER2– breast canc
Spring L. M. et al; npj Breast Cancer 2025
Read More
-
Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasi
Foldi J; JCO Precision Oncology 2025
Read More
-
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpas
Mittendorf E. A. et al; Nature Medicine 2025
Read More
-
Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study
Reason E. H. et al; Ann Surg Oncol 2025
Read More
-
Detection and Monitoring of Breast Cancer Local Recurrence Via Circulating Tumor DNA Minimal Residual Disease Assay
Prasath V, et al; JCO Precision Oncology 2025
Read More
-
Circulating tumor DNA refines risk stratification of neoadjuvant therapyresistant breast tumors
Magbanua M. J. et al; Nature Communications 2025
Read More
-
Exploring the utility of ctDNA testing in high-risk breast cancer patients in a community setting: case series
Wong K, et al; Ther Adv Med Oncol 2025
Read More
-
Meet Jon, Muscle-Invasive Bladder Cancer (MIBC) Survivor and Signatera Patient
Read Article
-
Dr. Barry Rosen - Nothing Else Compares
Dr. Barry Rosen answers the question to "Why did you start incorporating MRD in your practice?" Dr. Rosen discusses why he incorporated MRD testing into their patient care algorithm. They note that tr
Watch Video
-
PARPi Study Publication Summary
Read More
-
Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study
Nakamura Y. Reiter J.G. Natarajan P. et al. npj Precis. Onc. 2026
Read More
-
Meet Amanda, Colorectal Cancer Survivor and Signatera Patient
Read Article
-
Meet Amanda, Colorectal Cancer Survivor and Signatera Patient
Amanda shares her powerful and unexpected journey. A routine genetic screening during her pregnancy led to a Stage IV colon cancer diagnosis. She underwent chemo while pregnant, had surgery after her
Watch Video
-
How to Prepare for Your Next MRD Test: Practical Tips and FAQs
Read Article
-
Looking Back at 2025: How Natera Supported Cancer Survivors
Read Article
-
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
Zhang et al. JAMA Oncology 2025
Read More
-
Integrating ctDNA and utDNA Across the Bladder Cancer Continuum
Watch Video
-
Inform timing on adding CTLA-4 to PD-1 monotherapy
Read More
-
Loading More...
